ClinicalTrials.gg
TerminatedNCT06756035Updated Nov 5, 2026

CT-95 in Advanced Cancers Associated With Mesothelin Expression

A Phase 1 interventional study of CT-95 in Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer and Malignant Pleural Mesothelioma, Advanced, sponsored by Context Therapeutics Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Context Therapeutics Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
Updated Nov 5, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 28 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Enrollment
281st of 381
19 · median 35
Started
2025
with 6 others
Phase 1
153 of 500
9 open now
Registered
489th of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 281st largest by enrollment of the 381 interventional ones that give a count, is one of 7 that started in 2025, is one of 153 in phase 1, and was the 489th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 101 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

28 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 49 (65%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

Read the detailed description

Phase 1a Dose Escalation: Participants with ovarian epithelial tumors, primary peritoneal or fallopian tube cancer (PROC), epithelioid mesothelioma, lung adenocarcinoma, pancreatic adenocarcinoma, colorectal cancer, cholangiocarcinoma, and gastric/GEJ adenocarcinomas will be enrolled in one of approximately 9 dose escalation cohorts to assess the safety and tolerability of CT-95, as well as determine the maximum tolerated dose (MTD) or other recommended dose(s) for expansion (RDE[s]) for further dose expansion cohorts.

Participants will receive CT-95 as a single agent administered once weekly (QW) intravenously (IV) over a 4-week cycle.

Phase 1b Dose Expansion: The RDE(s) of CT-95 determined in Phase 1a will be evaluated in 2-4 indication-specific expansion cohorts of up to 20 subjects each (i.e. up to 80 participants total). Different indications, dose levels, and/or schedules may be explored. The expansion doses and/or dosing schedules for Phase 1b will be determined by Sponsor in conjunction with SRC based upon all available safety, PK, PD, biomarker, and preliminary efficacy data from Phase 1a.

03

Conditions studied

  • Mesothelin-Expressing Tumors
  • Epithelial Ovarian Cancer
  • Malignant Pleural Mesothelioma, Advanced
  • Malignant Peritoneal Mesothelioma, Advanced
  • Pancreatic Adenocarcinoma Advanced or Metastatic
  • Lung Adenocarcinoma Metastatic
  • Cholangiocarcinoma Advanced
  • Cholangiocarcinoma Non-resectable
  • Mesothelin-expressing Advanced Cancers
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Colorectal Cancer

Keywords

  • Phase 1 Dose Escalation Study
  • CT-95
  • Advanced, recurrent cancers
  • Unresectable, metastatic cancers
  • Cancers associated with mesothelin expression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 0 or 1
  • Subjects with evaluable disease per 1.1 or
  • Subjects with adequate organ function.
  • Subjects with advanced cancers associated with mesothelin expression

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.
  • Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
  • Concurrent participation in another clinical trial.
  • Evidence of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    CT-95

    Phase 1a: Dose Escalation - each dose cohort will assess toxicity 28 days following the first dose of CT95 anticipate a total of 8 dose cohorts. Phase 1b: Dose Expansion - approximately 80 participants will be evaluated in 2-4 indication-specific expansion cohorts.

    Drug: CT-95

Interventions

  • DrugCT-95

    MSLN bispecific antibody to be administered according to the dose and schedule of the assigned cohort until documentation of disease progression (or confirmed disease progression), unacceptable toxicity, or participant/physician decision.

06

What researchers measure

Primary outcomes

  1. Determine the MTD or RD of CT-95 [Safety and Tolerability]

    The frequency of dose-limiting toxicities (DLTs) will be analyzed along with safety and tolerability measures to determine the MTD or RD of CT-95.

    Time frame: From date of first dose of CT-95 until 28 days following the first dose.

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The frequency and severity of adverse events, serious adverse events, and adverse events of special interest will be analyzed.

    Time frame: From date of first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.

Secondary outcomes

  1. Evaluate Response Rates [Anti-tumor Activity]

    Overall response rates will be calculated using RECIST 1.1 (and mRECIST for patients with mesothelioma) for CT-95.

    Time frame: At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first

  2. Evaluate Progression-free Survival [Anti-tumor Activity]

    PFS will be summarized using RECIST 1.1 (and mRECIST for patients with mesothelioma) for CT-95.

    Time frame: At 8-week intervals from the time of the first dose of CT-95 for approximately 6 months or until treatment discontinuation, whichever comes first.

  3. Evaluate Overall Survival [Survival]

    Overall survival will be summarized for CT-95.

    Time frame: From the time of the first dose of CT-95 until approximately two years post-first dose.

  4. Evaluate the Maximum Serum Concentration (Cmax) [Pharmacokinetics]

    Serum concentrations of CT-95 analyzed as a function of time relative to dosing will be calculated.

    Time frame: From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.

  5. Evaluate the Area Under the Curve (AUC) [Pharmacokinetics]

    The AUC of CT-95 analyzed as a function of time relative to dosing will be calculated.

    Time frame: From date of first dose of CT-95 for 5 months or treatment discontinuation, whichever comes first.

  6. Evaluate Anti-Drug Antibodies [Immunogenicity]

    Incidence and titer of ADAs will be evaluated.

    Time frame: From date of first dose of CT-95 for 5 months or until treatment discontinuation, whichever comes first.

07

Study locations

8 sites
  • Context Investigational Site
    Denver, Colorado 80218, United States
  • Context Investigational Site
    Chicago, Illinois 60637, United States
  • Context Investigational Site
    Grand Rapids, Michigan 49546, United States
  • Context Investigational Site
    Hackensack, New Jersey 07601, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Context Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Context Investigational Site
    Nashville, Tennessee 37203, United States
  • Context Investigational Site
    San Antonio, Texas 78229, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Oct 2026, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2028 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Jan 1, 2025
StartActual
Mar 31, 2025
Primary completionActual
Oct 9, 2026was Dec 2026
CompletionActual
Oct 9, 2026was Dec 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
changed Nov 5, 2026
Sites
1 site removed
Show 1 removed
  • Context Investigational Site · San Antonio, United States
Nov 5, 2026
Primary completion
Dec 2026→Oct 9, 2026 (actual)
Nov 5, 2026
Study completion
Dec 2028→Oct 9, 2026 (actual)
Nov 5, 2026
Enrollment
70 (estimated)→19 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Terminated
    Why stopped The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
    1 site removed
    Show 1 removed
    • Context Investigational Site · San Antonio, United States
    Primary completion Dec 2026→Oct 9, 2026 (now actual)
    Study completion Dec 2028→Oct 9, 2026 (now actual)
    Enrollment 70 (estimated)→19 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06756035
Lead sponsor
Context Therapeutics Inc.
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Mar 31, 2025
Primary completion
Oct 9, 2026
Completion
Oct 9, 2026
Last update
Nov 5, 2026

Study contacts

Karen Chagin, MD
study director · Context Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion